Elan shares fall as drug fails test

Shares in Elan fell yesterday when, together with US company Biogen, it announced that the Drug Antegren, failed an important clinical trail.

Antegren is an experimental drug for Crohn’s disease, an inflammatory bowel condition affecting around one million people globally.